Jack Allen

Michael Okunewitch

Gum-Ming Lowe

Joseph Pantginis

Sean McCutcheon

William Wood

Kevin Kuo

Kristen Kluska

Lucy De Yang

Mayank Mamtani

- Lineage Cell Therapeutics, Inc. (LCTX) has entered into a **three-year research collaboration** agreement with William Demant Invest A/S (WDI).  **[876343_0000950170-25-111319_lctx-ex9_1.htm:0]** **[876343_0000950170-25-111319_lctx-20250826.htm:1]** 
- The collaboration, announced on **August 26, 2025**, focuses on advancing the preclinical development of Lineage's auditory neuronal cell transplant, **ReSonance (ANP1)**, for the treatment of hearing loss.  **[876343_0000950170-25-111319_lctx-ex9_1.htm:0]** **[876343_0000950170-25-111319_lctx-20250826.htm:1]** 
- William Demant Invest will fund **up to $12 million** in research collaboration costs over the period.  **[876343_0000950170-25-111319_lctx-ex9_1.htm:0]** **[876343_0000950170-25-111319_lctx-20250826.htm:1]** 
- The main objective of the agreement is to complete a preclinical phase, aiming for readiness to potentially progress to human clinical trials.  **[876343_0000950170-25-111319_lctx-20250826.htm:1]**

Lineage Cell Therapeutics Announces Research Collaboration with William Demant Invest

Lineage Cell Therapeutics (LCTX)